Reuters logo
BRIEF-Lotus Pharmaceutical passes Korea MFDS approval for new drug application
September 7, 2017 / 3:30 AM / 2 months ago

BRIEF-Lotus Pharmaceutical passes Korea MFDS approval for new drug application

Sept 7(Reuters) - Lotus Pharmaceutical Co Ltd :

* Says it received approval for Tegafur 20mg/Gimeracil 5.8 mg/Oteracil potassium 19.6 mg Capsule and Tegafur 25mg/Gimeracil 7.25 mg /Oteracil potassium 24.5 mg Capsule (TS-1), from South Korea Ministry of Food and Drug Safety, MFDS

* The new drug TS-1 is used for treatment of gastric cancer, head and neck cancer as well as pancreatic cancer

* Company will be able to sell TS-1 in South Korea after receiving approval

Source text in Chinese: goo.gl/ZQsjX4

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below